Use this guide one step at a time.
Pancreatic cancer can create urgent practical problems while the treatment plan is still being assembled. The first questions are what type of pancreatic tumor this is, whether it can be removed surgically, and whether jaundice, pain, weight loss, poor digestion, or diabetes needs attention now.
Subtypes and biomarkers
Most pancreatic cancers are exocrine pancreatic ductal adenocarcinomas. Pancreatic neuroendocrine tumors arise from hormone-producing cells and use different staging and treatment, so the pathology label matters. Less common exocrine forms may also warrant expert review. For ductal adenocarcinoma, anatomy is as important as the formal TNM stage: teams often classify a tumor as resectable, borderline resectable, locally advanced, or metastatic based partly on contact with major blood vessels. This category can change after treatment and expert imaging review. Germline testing looks for inherited variants, including BRCA1, BRCA2, PALB2, and mismatch-repair genes, that may affect treatment and relatives. Tumor molecular profiling can find rare actionable changes, such as deficient mismatch repair, high microsatellite instability, high tumor mutational burden, NTRK fusions, or other targets. A germline finding and a tumor finding are not interchangeable. CA 19-9 is a blood marker that may help establish a baseline and follow response, but bile-duct blockage can raise it and some people do not produce it.
What is pancreatic cancer?
The pancreas lies behind the stomach and contains exocrine cells that make digestive enzymes and endocrine cells that make hormones. This page focuses on exocrine pancreatic cancer, especially pancreatic ductal adenocarcinoma. Neuroendocrine tumors have distinct staging and treatment. Exocrine cancer may spread early through nearby vessels, lymph nodes, the liver, the peritoneum, or other sites. Cigarette smoking, chronic pancreatitis, diabetes, obesity, age, family history, and inherited variants can increase risk, but most affected people do not have a clearly identifiable inherited cause. There is no routine population screening test. People with strong inherited or familial risk may be offered surveillance in specialized programs. Treatment planning commonly classifies disease as resectable, borderline resectable, locally advanced, or metastatic because the relationship to major blood vessels affects surgery. Germline testing and tumor molecular profiling can reveal uncommon but actionable findings. Care depends on type, extent, resectability, biomarkers, health, and preferences.
Signs and symptoms
Early pancreatic cancer may not cause symptoms. Tumors in the pancreatic head can block bile flow, leading to yellow skin or eyes, dark urine, pale or greasy stool, and itching. Other possible findings include pain in the upper or middle abdomen that may reach the back, loss of appetite, unexplained weight loss, nausea, vomiting, fatigue, bloating, diarrhea, or new difficulty digesting fatty foods. New-onset diabetes or unexpectedly worsening diabetes can sometimes be associated. A blood clot may be the first sign in some people. Gallstones, hepatitis, ulcers, pancreatitis, diabetes, spine problems, and many other noncancer conditions can cause similar symptoms. Persistent jaundice, weight loss, or abdominal or back pain warrants medical assessment; fever with jaundice or severe vomiting may require urgent care.
Diagnosis and staging
Evaluation usually includes history, examination, liver and other blood tests, and pancreas-protocol CT or MRI. Endoscopic ultrasound provides detailed imaging and can guide needle biopsy. ERCP may be used to relieve bile-duct blockage and obtain samples, rather than as the primary diagnostic test. Biopsy confirms the type when needed before drug or radiation treatment; some clearly resectable tumors proceed directly to surgery. CA 19-9 can support assessment and follow-up but cannot diagnose cancer and may rise from benign bile obstruction. Staging uses imaging and sometimes laparoscopy to assess local vessels, lymph nodes, peritoneum, liver, lungs, and other sites. TNM stage is recorded, while resectable, borderline resectable, locally advanced, and metastatic categories guide planning. Germline testing is generally considered for all patients, and tumor profiling may identify treatment biomarkers. Care depends on type, extent, resectability, biomarkers, organ function, and preferences. Multidisciplinary review can clarify resectability when vascular involvement is uncertain.
Established treatment paths
Surgery offers the main opportunity for long-term disease control when an exocrine tumor can be completely removed. Operations include the Whipple procedure for tumors in the pancreatic head and distal pancreatectomy for body or tail tumors. Chemotherapy is usually given after surgery and may be given before surgery for resectable or borderline-resectable disease; radiation is used selectively. Locally advanced unresectable cancer is generally treated with systemic chemotherapy, sometimes followed by chemoradiation or focused radiation in selected cases. Metastatic disease is treated with combination or single-agent chemotherapy according to fitness and goals. Biomarker-directed options may include PARP inhibition for selected inherited BRCA-related cancers, immunotherapy for rare mismatch-repair-deficient tumors, or other targeted drugs for uncommon actionable alterations. Biliary or gastric outlet obstruction may require a stent or bypass. Pancreatic enzyme replacement, diabetes care, nutrition support, and pain procedures are important parts of treatment. Clinical trials are appropriate to consider at any stage. The plan depends on resectability, stage, molecular findings, symptoms, prior treatment, health, and preferences. Early palliative-care involvement can support symptom control alongside disease-directed therapy.
Supportive care
Early supportive care is particularly important for weight loss, weakness, pain, nausea, vomiting, jaundice, itching, and difficulty eating. Pale or greasy stools, bloating, or continued weight loss can suggest pancreatic enzyme insufficiency; the team can assess enzyme replacement and dietitian support. Bile-duct or stomach-outlet blockage may need an endoscopic stent or another procedure. Pain care can include medicines, radiation, or a celiac plexus procedure, depending on the cause. Diabetes and blood sugar may change during illness or after surgery and need coordinated management. Pancreatic cancer also raises blood-clot risk, so new one-sided leg swelling, chest pain, or sudden breathlessness needs prompt assessment. Palliative care can work alongside chemotherapy or surgery.
Profiles documenting pancreatic cancer care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
Sources
Source information checked: 2026-10-01. The links below identify the public and clinic-provided materials used for this page.
- NCI: Pancreatic Cancer ↗Checked 2026-09-29
- NCI: Pancreatic Cancer Treatment ↗Checked 2026-10-01
- NCI PDQ: Pancreatic Cancer Treatment ↗Checked 2026-09-29
- NCI: What Is Pancreatic Cancer? ↗Checked 2026-10-01
- NCI: Pancreatic Cancer Testing and Diagnosis ↗Checked 2026-10-01
How Cancer Clinic Finder compiles information · Suggest a factual correction
